Drug Search Results
More Filters [+]

CLR-325

Alternative Names: clr-325, clr325, clr 325
Latest Update: 2019-08-16
Latest Update Note: Clinical Trial Update

Product Description

For chronic stable heart failure

Mechanisms of Action: APJ Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CLR-325

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Heart Failure, Chronic|Heart Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CCLR325X2202

P2

Completed

Heart Failure

2019-01-14

CCLR325X2202

P2

Completed

Heart Failure, Chronic

2019-01-14

Recent News Events

Date

Type

Title